Related Experiment Video
Updated: Feb 2, 2026

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
Published on: December 22, 2020
Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth
Priscila Fabiana Rodrigues1, Sara Matarazzo2, Federica Maccarinelli2
1Laboratory of Inflammation and Cancer, Department of General Biology - ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Abstract:
Fibrosarcomas are soft tissue mesenchymal tumors originating from transformed fibroblasts. Fibroblast growth factor-2 (FGF2) and its tyrosine-kinase receptors (FGFRs) play pivotal roles in fibrosarcoma onset and progression, FGF2 being actively produced by fibroblasts in all stages along their malignant transformation to the fibrosarcoma stage. The soluble pattern recognition receptor long pentraxin-3 (PTX3) is an extrinsic oncosuppressor whose expression is reduced in different tumor types, including soft tissue sarcomas, via hypermethylation of its gene promoter. PTX3 interacts with FGF2 and other FGF family members, thus acting as a multi-FGF antagonist able to inhibit FGF-dependent neovascularization and tumor growth. Here, PTX3 overexpression significantly reduced the proliferative and tumorigenic potential of fibrosarcoma cells in vitro and in vivo. In addition, systemic delivery of human PTX3 driven by the Tie2 promoter inhibited the growth of fibrosarcoma grafts in transgenic mice. In a translational perspective, the PTX3-derived small molecule FGF trap NSC12 prevented activation of the FGF/FGFR system in fibrosarcoma cells and reduced their tumorigenic activity in vivo. In conclusion, impairment of the FGF/FGFR system by FGF trap molecules may represent a novel therapeutic approach for the treatment of fibrosarcoma.
Insights
Long pentraxin-3 (PTX3) acts as an oncosuppressor by inhibiting fibroblast growth factor-2 (FGF2) signaling. PTX3 overexpression or FGF trap molecules show therapeutic potential against fibrosarcoma by reducing tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Fibrosarcomas are malignant soft tissue tumors driven by fibroblast growth factor-2 (FGF2) and its receptors (FGFRs).
- Long pentraxin-3 (PTX3) is an oncosuppressor that inhibits FGF signaling but is downregulated in tumors, including soft tissue sarcomas, due to gene promoter hypermethylation.
Purpose of the Study:
- To investigate the therapeutic potential of PTX3 and FGF trap molecules in fibrosarcoma.
- To evaluate the impact of PTX3 on fibrosarcoma cell proliferation and tumor growth.
Main Methods:
- Assessed PTX3 effects on fibrosarcoma cells in vitro and in vivo.
- Utilized transgenic mice for systemic PTX3 delivery.
- Tested the efficacy of the PTX3-derived small molecule FGF trap, NSC12, in fibrosarcoma models.
Main Results:
- PTX3 overexpression significantly reduced fibrosarcoma cell proliferation and tumorigenicity.
- Systemic PTX3 delivery inhibited fibrosarcoma graft growth in mice.
- NSC12 prevented FGF/FGFR activation and reduced fibrosarcoma tumor activity.
Conclusions:
- PTX3 acts as a potent inhibitor of fibrosarcoma growth.
- Targeting the FGF/FGFR system with FGF trap molecules represents a promising therapeutic strategy for fibrosarcoma treatment.
More Related Videos
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Population Growth
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
Meristems and Plant Growth

